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Abstract
Background—Preclinical evidence suggested that blockade of the PI3K/AKT/mTOR pathway
might overcome resistance to hormonal therapy.
Methods—We performed a randomized phase II trial of intravenous temsirolimus 25 mg weekly
versus the combination of weekly temsirolimus with a regimen of megestrol acetate 80 mg bid for
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three weeks alternating with tamoxifen 20 mg bid for three weeks in women with recurrent or
metastatic endometrial carcinoma.
Results—There were 71 eligible patients who received at least one dose of therapy with 21 of
these treated on the combination arm which was closed early because of an excess of venous
thrombosis, with 5 episodes of deep venous thrombosis (DVT)and 2 pulmonary emboli. There
were three responses observed in that arm (14%). A total 50 eligible patients were treated on the
single agent arm with 3 episodes of DVT and 11 responses (22%). Response rates were similar in
patients with prior chemotherapy (7 of 29; 24%) and those with no prior chemotherapy (4 of 21;
19%). Two of four patients with clear cell carcinoma responded.
Conclusions—Adding the combination of megestrol acetate and tamoxifen to temsirolimus
therapy did not enhance activity and the combination was associated with an excess of venous
thrombosis. Temsirolimus activity was preserved in patients with prior adjuvant chemotherapy.
These findings will have implications for future trial design.
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INTRODUCTION
Advanced or recurrent endometrial carcinoma is an incurable disease with short overall
survival. Standard initial therapy for many years consisted of treatment with
medroxyprogesterone acetate or megestrol acetate, and response rates of 15%–27% to
progestin-based regimens in chemotherapy-naïve patients have been published by a number
of authors [1,2]. However the median progression-free survival with such regimens is short,
and although low-grade and estrogen or progesterone receptor-positive tumors have higher
response rates to endocrine therapy, no reliable predictive factors for benefit have emerged
[3]. Currently, most women with advanced disease are initially treated with platinum/taxane-
based chemotherapy. Such regimens yield response rates in the range of 50%, but the
median survival remains only about 12–15 months [4].
As targeted agents began to show promise in a number of different tumor types, interest was
focused on the high frequency of aberrations in the PI3K/Akt/mTOR pathway in
endometrial cancers [5]. A number of mTOR inhibitors have been tested in endometrial
cancer and found to have only modest activity (Table 1). Phase II studies of temsirolimus
conducted by the National Cancer Institute of Canada (NCIC) showed a 14% response rate
in chemotherapy-naïve patients and a 4% response rate in patients with prior chemotherapy
[6].
In endometrial cancer cell lines and mouse models, upregulation of PI3K/Akt/mTOR
pathway activity is associated with resistance to progestin therapy, and inhibition of the
pathway can reverse this resistance [7,8]. Similar observations have been made regarding
the association of resistance to tamoxifen and aromatase inhibitors with PI3K/Akt/mTOR
pathway activity in breast cancer models. These led to a phase III trial in which breast
cancer patients previously treated with a nonsteroidal aromatase inhibitor who were
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randomized to the combination of the mTOR inhibitor, everolimus, plus exemestane had
significantly superior progression-free survival compared to those randomized to
exemestane alone [9].
We therefore performed a randomized open-label two-stage phase II trial of temsirolimus
alone versus the combination of temsirolimus plus a hormonal therapy regimen consisting of
alternating megestrol acetate and tamoxifen. This hormonal therapy was chosen based on
data published by the Gynecologic Oncology Group (GOG) showing a response rate of 27%
and a median response duration of 28 months with the regimen [2]. While there are no data
showing that such a regimen is superior to single agent progestin therapy, regimens
including periodic tamoxifen have produced the highest response rates in the GOG




Subjects were required to have measurable endometrial carcinoma (RECIST version 1.0)
that was either stage III or IV, or persistent or recurrent after treatment for earlier stage
disease. Prior endocrine therapy was prohibited; up to one prior chemotherapy regimen was
allowed, but if that regimen were administered in the setting of stage IV disease it was
required that the patient have been without evidence of disease at the completion of
chemotherapy, and to have had at least six months of progression-free survival since the
completion of chemotherapy. Chemoradiotherapy was counted as a chemotherapy regimen.
Other eligibility criteria included performance status 0–2, absolute neutrophil count ≥ 1,500/
mcl, platelets ≥ 100,000/mcl, total bilirubin ≤ institutional upper limit of normal (ULN),
AST and alkaline phosphatase ≤ 2.5 times ULN (≤ 5 times ULN for subjects with liver
metastases), creatinine ≤ 1.5 × ULN, fasting cholesterol ≤ 350 mg/dL, fasting triglycerides ≤
400 mg/dL, and albumin ≥ 3.0 mg/dL. Long term corticosteroid use as well as enzyme-
inducing antiepileptic drugs and other CYP3A4 inducers were prohibited. Patients with
known congestive heart failure or a need for oxygen use were excluded, as were those with a
history of unprovoked deep venous thrombosis (DVT) or pulmonary embolus (PE), unless
maintained on anticoagulation for the duration of the trial. All subjects signed an
institutionally approved informed consent including HIPAA authorization. Central review of
initial pathologic diagnosis by the GOG Pathology Committee was performed for all cases.
Study Design and Treatment Plan
Treatment was randomly assigned with equal probability within strata as either single agent
temsirolimus at a dose of 25 mg intravenously (IV) weekly or the combination of
temsirolimus 25 mg IV weekly plus megestrol acetate 80 mg orally twice a day for 3 weeks
alternating with tamoxifen 20 mg orally twice a day for 3 weeks. Randomization was
stratified on the basis of prior chemotherapy (yes or no). After closure of the combination
arm, accrual to single agent temsirolimus therapy continued. A letter describing the risk of
thrombosis was sent to physicians and patients on the combination therapy arm, and they
were allowed to choose whether to remain on their current regimen, receive temsirolimus
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alone, or to discontinue protocol-directed therapy. Therapy was to be continued until tumor
progression or undue toxicity.
Management of Toxicity
Administration of subsequent doses of temsirolimus required ANC > 1,000/mcl and platelets
> 100,000/mcl. Temsirolimus was held until these parameters were met and restarted with a
5 mg dose reduction. Tamoxifen and megestrol acetate could be continued while
temsirolimus was held. Subjects experiencing a venous thrombotic event were permitted, at
the discretion of the investigator, to stay on study with institution of therapeutic
anticoagulation. Toxicities requiring cessation of treatment included: grade 2 or higher
pneumonitis, requirement for a dose reduction of temsirolimus to less than 15 mg, and grade
3 or 4 toxicities requiring over 14 days till recovery to tolerable grade 2 or better.
Evaluation
Toxicity was graded according to CTCAE version 3.0. Re-evaluation for disease response
was performed every six weeks for the first 24 weeks of therapy, and then every 12 weeks.
RECIST criteria versions 1.0 were used for assessment of response. The categories of
confirmed, complete and partial response were combined to define tumor response.
Progression-free survival (PFS) was defined as the time from study entry to death or
documentation of disease progression. Patients alive with no evidence of disease progression
were censored at the time of their last follow-up. Survival (OS) was defined as the time from
study entry to death, regardless of cause; patients last known to be alive were censored at
time of last follow-up.
Immunohistochemical Analysis
Formalin-fixed, paraffin-embedded (FFPE) tissue sections were sent to the GOG Tissue
Bank and distributed to the GOG Core Laboratory for Receptors and Targets. Before
beginning the experiments, immunostaining protocols and antibody dilution for Estogen
Receptor-alpha (ER; Dako, Carpinteria, CA), Progesterone Receptor (PR; Dako,
Carpinteria, CA), Progesterone Receptor B (PRB; Cell signaling, Beverly, MA), Ser-473
phospho-AKT XP (pAKT; Cell signaling, Beverly, MA), and PTEN (Millipore, Billerica,
MA) were tested and optimized on positive and negative control tissues. Tissue hydration
and deparafinization was performed by incubating the slides in three washes of xylene,
followed by three washes of ethanol and finally three washes of water. Antigen retrieval was
initiated by microwaving the slides at sub-boiling temperatures in 10mM of sodium citrate
buffer with pH 6.0 for 10min for ER and pAKT, and 20 min for PR, PRB and PTEN. The
slides were then cooled at room temperature for 30 min. Quenching of endogenous
peroxidases was achieved by incubating the sections in 3% hydrogen peroxide for 10 min.
The sections were then rinsed and blocked using 5% normal goat serum for 30 min (PR,
PRB and PTEN) to 1 hour (pAKT), followed by overnight incubation at 4 °C in the primary
antibodies listed above. Tissues were then rinsed and incubated for 30 min in biotinylated
goat anti-mouse antibody for PR, goat anti-rabbit for PRB and PTEN, mouse DAKO
EnVision ™ HRP System for ER, and SignalsStain ™ Boost Detection Reagent for pAKT.
After rinsing, the sections were incubated in DAB chromogen substrate, counterstained
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using hematoxylin, dehydrated using three washes of ethanol and xylene, and mounted with
coverslips.
The slides were reviewed independently by two investigators (KL, HR) blinded to the
treatment regimen and clinical outcome. The proportion and intensity of staining was
recorded as 0–100% and 0 to 4+, respectively. These values were multiplied together to
determine a modified H-score. Discrepancies of more than 20% in the modified H-score
values were adjudicated by a member of the GOG Pathology Committee, Dr Meenakshi
Singh. The staining was further reviewed by RZ; no significant differences in staining or
interpretation were found. Because of the variable age of the slides, it was assumed that
there would be general, but variable, loss of immunoreactivity. Therefore, although modified
H-scores were calculated for most of the analyses performed, any level of staining for any of
the stains was considered positive and results were simply dichotomized as positive or
negative. However, the continuous version of the modified H score was used for identifying
correlation between markers and for the proportional hazards model.
Statistical Considerations
The primary endpoint of the trial was clinical complete or partial response. The first stage of
the trial was to be stopped after accrual of 21 patients to each arm, with the number of
responses required to go to the second stage dependent on how many patients had prior
chemotherapy.
A two-stage conditional stratified phase II trial as proposed by London and Chang was used
which utilizes the marginal number of responses across all populations while factoring
differing probabilities of response within each population [10]. Conditioned on the realized
sample size in each stratum, the probability mass function for R1 and R2 corresponding to
the responses produced in stages 1 and 2 can be found with:
where i indexes the k=2 important stratification levels under consideration and j indexes the
stage of accrual. The distribution of Rj depends on the probabilities of response, pi, within
each stratum. Stratum 1 corresponded with those patients who had never been treated with
chemotherapy whereas stratum 2 corresponded with those patients who had prior
chemotherapy. The null hypothesis of no treatment effect is H0: p1 = 0.20 and p2 = 0.10.
Under the alternative hypothesis of H1: p1 = 0.40 and p2 = 0.30, the following design will
limit the probability of type I error to 0.06 and type II to 0.10. A confidence interval for the
true response rate, adjusted for multistage design when appropriate, is reported for each arm
[11].
Translational research endpoints were analyzed in an exploratory manner and were not
considered when determining the sample size of this trial. Beyond basic summary statistics,
the Spearman rank-order correlation statistic was used to assess correlation between
biomarkers [12]. The Jonckheere-Terpstra test was used to test the association of biomarker
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modified H-score with increasing tumor grade [13]. The modified H-score was collapsed
into two categories for some analyses; 0 (no expression) and greater than 0 (any expression).
Fisher’s exact test was used to test 2 by 2 associations between biomarker expression and
RECIST response [14]. A Cox proportional hazards model was fit for each biomarker to
assess the association of modified H-score with progression-free and overall survival [15].
Kaplan-Meier estimates of the distribution of survival and progression-free survival times
were plotted by treatment arm and by biomarker expression combined with treatment arm
[16].
RESULTS
Seventy-three patients were registered to this trial between 9/29/08 and 11/22/10. Two were
excluded from analysis; one did not meet eligibility requirements after central review and
one never received any protocol therapy. Figure 1 (supplemental) shows the outcomes of all
patients registered to the trial. Patient characteristics are shown in Table 2. At the time of
writing two patients on the single agent temsirolimus arm were still receiving therapy at 30
and 45 months from enrollment.
Adverse Events
On 10/19/09 the trial was suspended and the combination arm was permanently closed to
accrual because an excess of venous thromboses was noted. At this time 22 patients had
been treated on combination therapy (one of whom was ineligible), and there had been five
events of deep venous thrombosis (DVT), two pulmonary emboli, one myocardial
infarction, and one sudden death. At that time point there had been no thrombotic events
reported among the 21 patients on the single agent temsirolimus arm; subsequently three
patients receiving single agent temsirolimus experienced a DVT. The p-value for Fisher’s
exact test of an association between treatment arm and thrombotic events at the time the trial
was closed is 0.048.
Other key adverse events are shown in Table 3 (supplementary), and are generally those
expected from mTOR inhibitors. The most common side effects overall included low-grade
myelosuppression, rash, fatigue, hyperlipidemia, edema, pneumonitis, and gastrointestinal
toxicities including nausea, diarrhea, anorexia and mucositis. On the single agent
temsirolimus arm 11 patients (22%) came off study treatment for toxicity which mandated
cessation of study therapy per protocol, and 5 (10%) of patients wished to stop therapy in
absence of progression or protocol-specified toxicity. On the combination arm study
treatment was discontinued in six patients (28.6%) for protocol-specified toxicity and in one
(4.8%) for patient preference. Seven patients were removed from protocol therapy because
of pneumonitis, (two on the combination arm and five on the single agent arm, including one
who died). Two patients, one on each arm, came off study for edema. Twenty-two percent of
the women treated on this trial (n=16) were seventy years or older. They did not have an
overall excess of toxicity, although fatigue may have been more common. Grade ≥ 3 fatigue
was seen in 3/55 (5.4%, all grade 3) of women younger than 70 and 2/16 (12.5%, one grade
3 and one grade 4) of women aged 70 or older. For mucositis, 2/16 (6%) of women aged ≥
70 experienced grade 2 symptoms versus 7/55 (12.7%) of younger women.
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At the time the combination arm was closed, 3/21 (14%; 94% confidence interval 3%–36%)
eligible patients had a partial response, which would have met the criteria to proceed to
second stage. Histologic subtypes of the responding tumors were: one grade 1 endometrioid,
one grade 3 endometrioid, and one grade 2 adenocarcinoma, not otherwise specified. No
further patient on this arm subsequently met criteria for a response. Six of the first 21
patients in the single agent temsirolimus arm had a response, and a total of 50 eligible
patients were treated on that arm. There were 11 responses (22%; 94% confidence interval
11%--52%), three complete responses (CR) and eight partial responses (PR). Histologic
subtypes of responding tumors were: one grade 1 endometrioid, three grade 2 endometrioid,
two grade 3 endometrioid, one mixed, two serous, and two clear cell. The median duration
of response was 8.5 months. Twenty-six patients had stable disease (SD) as their best
response, with a median duration of 7.9 months. Breakdown of responses by prior therapy is
seen in Table 4. On the single agent temsirolimus arm, the response rate was 24% for
patients with prior chemotherapy and 19% for those with no prior therapy. Progression-free
and overall survival by arm are shown in Figure 2a. Median progression-free and overall
survival (both arms combined) were 4.9 months and 10.8 months for those with prior
chemotherapy versus 8.2 months and 20.7 months for those without (Figure 2b).
Information on use of concomitant medications was collected at baseline. Five patients were
on metformin. None of the three patients on metformin who were randomized to single
agent temsirolimus had a major response (1 progressive disease (PD), 2 SD), and one of the
two on the combination of temsirolimus plus hormonal therapy responded (1PR, 1 PD).
Seven patients were receiving angiotensin converting enzyme (ACE) inhibitors at time of
study registration; none developed pneumonitis. Information on changes in medications
during the trial was not collected.
Immunohistochemistry
Of the 73 patients enrolled in the study, three were deemed ineligible, seven did not have
primary tissue available for study, and five had an insufficient number of FFPE slides to
complete the analysis. Of the 58 remaining cases, two were judged to have no remaining
tumor tissue on the submitted slides, leaving a total of 56 patients included in the analysis:
36 on single agent temsirolimus and 20 on combination therapy. After immunostaining was
performed, 30 cases were found to be positive for PR, 35 for PRB, 20 for ER, 11 for pAKT,
and 30 for PTEN (Figure 4).
Of the 11 cases that stained for pAKT (regardless of PTEN status), nine were treated on
single agent temsirolimus, and four achieved a clinical response. Neither of the two patients
staining for pAKT responded in the combination arm. Response data by pAKT is shown in
Table 5 (supplementary). The association of pAKT with OS for each treatment arm is shown
in Figure 3a. Twenty-four tumors were negative for pAKT and positive for PTEN. Of these
cases, five patients had a clinical response. Twenty-one cases were negative for both pAKT
and PTEN. Only two responses were observed in this group. There was no statistically
significant association between pAKT or PTEN expression and response, but response
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estimates are consistent with fewer responders among those whose tumors were negative for
both pAKT and PTEN.
There was a statistically significant inverse correlation between PR H-score and tumor
grade; there was no significant association with grade for any of the other biomarkers. Both
of the responding tumors on the combination therapy arm showed positive staining for ER,
PR and PRB. The response to temsirolimus as a single agent did not significantly vary by
ER, PR or PRB expression status (ER− 24%, ER+ 27%; PR− 27%, PR+ 24%; PRB− 23%,
PRB+ 26%). The association of ER with OS for each treatment arm is shown in Figure 3b.
While it was not statistically significant, the hazard ratio (HR) estimates for a 100 unit
increase in modified ER H-score suggest a larger relative survival benefit in those with
higher ER H-scores compared with lower ER H-scores (HR=0.38; Wald 95% confidence
interval: 0.11 to 1.25) in the hormonal arm as compared with that in the non-hormonal arm
(HR=0.71; Wald 95% confidence interval: 0.35 to 1.45). This is consistent with the role of
ER as a potential predictive marker for response to hormone therapy [3]. Additionally, ER
and PR were positively correlated with each other.
DISCUSSION
This trial confirms the activity level of single agent temsirolimus in women with
endometrial cancer. The response rate in this group was 22%, which is very similar to that
reported by Oza et al (24% investigator-reported; 14% on independent radiology review) for
chemotherapy naïve patients [17] and considerably better than Oza et al observed in
pretreated patients (4%). This suggests that patients who would have met eligibility for our
trial, with prior adjuvant chemotherapy or at least six-month progression free interval since
prior chemotherapy in the setting of advanced disease, are more likely to respond to
temsirolimus than the average patient receiving second-line therapy for advanced disease.
Similar results have been found for second-line platinum-based therapy, with a higher
likelihood of response associated with a longer platinum-free interval. [18] We also
confirmed that responses are observed in all histologic subtypes of endometrial cancer. The
responses seen in two of four women with clear cell carcinoma are very encouraging for
benefit in women with that rare histology. As in other trials of mTOR inhibitors, there were
a few patients with prolonged benefit, including one who has been on study for 45 months.
The two women still on treatment at the time of data analysis both had tumors of
endometrioid histology (one grade1, and one grade 2).
We saw no evidence of increased benefit with the addition of a hormonal regimen consisting
of alternating megestrol acetate and tamoxifen to temsirolimus. This is not simply because
of increased toxicity. There was no trend to an improved response rate with the combination.
This is different from preliminary results reported by Slomovitz et al, who described no
responses to the mTOR inhibitor everolimus when it was given as a single agent to women
with progressive or recurrent endometrial cancer [19], whereas a successor trial in the same
population using the combination of letrozole plus everolimus produced a response rate of
31% [20]. A study with letrozole alone in women with chemotherapy-naïve advanced
endometrial cancer yielded a response rate of only 9.4% [21]. It is very possible that there
are mechanistic differences between the interactions of mTOR inhibitors with progestins
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versus aromatase inhibitors. However, while everolimus is approved for use in breast cancer
specifically in combination with an aromatase inhibitor, benefits to the addition of mTOR
inhibitors to tamoxifen have also been observed in two smaller randomized trials, suggesting
the effect in breast cancer may not be specific to only one hormonal agent [22,23]. Given
that our results showed a trend towards benefit to combination therapy in women with ER
positive tumors, we would suggest any future trials of the combination of mTOR inhibitors
and hormonal agents in women with endometrial cancer be limited to those with ER positive
tumors.
The increased rate of thrombosis that we observed is likely multifactorial. First, the regimen
of tamoxifen alternating with megestrol acetate is fairly thrombogenic by itself in women
with endometrial cancer. Four pulmonary emboli, 2 deep venous thromboses and one stroke
were reported among 56 women in the original publication (12.5% rate of thrombosis) [2].
This is higher than the 5% rate of venous thrombosis reported on prior GOG trials using
megestrol acetate alone [1] (which is similar to the 5% rate of venous thrombosis reported in
studies using megestrol acetate for appetite stimulation in women with cancer in general)
and was likely further increased by the insertion of central venous access devices for many
women in our study [24]. At least two of the reported thromboses appeared to be catheter-
related. Prophylactic anticoagulation should be considered in women with advanced
endometrial cancer treated on a combination of megestrol acetate and tamoxifen,
particularly if a central venous access device is in place. The thrombotic risk was likely
exacerbated by the edema that is a class effect of mTOR inhibitors, and may be related to
inhibition of lymphangiogenesis [25]. Eleven of 21 patients on the combination arm and 18
of 50 patients on the single agent temsirolimus arm reported grade 1 or greater edema and
edema per se was the reason for discontinuation of therapy in two patients. In addition, use
of temsirolimus can result in compensatory upregulation of phospho-AKT, which can
upregulate tissue factor. Interestingly, the TAMRAD trial, which randomized women with
metastatic breast cancer to tamoxifen alone or the combination of tamoxifen and everolimus
did not report an excess of venous thromboses in the combination arm; there were 2
episodes of DVT and one PE reported in the 57 women on tamoxifen alone and three
episodes of DVT described in the 54 women receiving combination therapy [22]. It is
possible that megestrol acetate is an important contributor to the risk of thrombosis or that
women with metastatic breast cancer, who do not tend to have pelvic disease, are less prone
to venous thrombosis than women with metastatic endometrial cancer.
Other toxicities on this trial were as reported in previous studies of mTOR inhibitors.
Pneumonitis remained problematic, and was the probable cause of one death as well as
resulting in discontinuation of protocol therapy for seven (10%) women. It has been reported
that ACE inhibitor therapy is protective against pneumonia [26] and radiation pneumonitis
[27]; none of the patients who developed pneumonitis were taking ACE inhibitors at the
time of study entry, but the numbers were small. Patients over the age of 70 years did not
have more toxicity in general, although severe fatigue appeared more common in this age
group.
We did not see any differences in response rates in women who were receiving metformin at
baseline in either the single agent of the combination arm. However, this does not refute the
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hypothesis that metformin treatment may be associated with better outcomes for endometrial
cancer patients, as we did not collect information on concomitant medications throughout
the study. Temsirolimus can cause hyperglycemia and we do not know which patients might
have started metformin during the trial.
GOG 248 was not powered to test translational research outcomes. We hypothesized that
tumors with loss of PTEN would exhibit activation of AKT as demonstrated by
phosphorylation at Ser-473 and vice versa, that is positive PTEN staining would be linked to
decreased pAKT. However, we observed that while the expected negative correlation
between PTEN and pAKT was present in a subset of tumors (Figure 4), other tumors were
positive or negative for both factors. Possible reasons for this are that PTEN mutations in
endometrial cancer do not always result in loss of PTEN immunohistochemical staining and
there can be other PI3K pathway alterations, such as PI3K or AKT mutation that result in
increased pAKT [28]. Other small studies have not shown any correlation between tumor
immunohistochemical markers and response to mTOR inhibitors in endometrial cancer. Oza
et al stained tissue for 58 of the 62 patients on their Temsirolimus trials for PTEN, pAKT,
pS6, and pmTOR, and found no correlation between response or progression and any marker
[29]. Tredan et al reported on immunohistochemical analyses of tumors from 36 of the 44
patients on the Endorad trial of single agent everolimus, and found that patient outcome was
not predicted by pAKT or PTEN expression, or by immunohistochemical results of staining
for ER/PR, HER2, LKB1, PI3K, 4E-BP1, p4E-BP1, or S6RP [30]. Our findings of a trend
towards pAKT status as a predictor of response to temsirolimus is supported by preclinical
work, [31] but may be due to chance as our numbers were small. The slides on this trial
were not all freshly cut; sites could provide blocks or unstained slides. We dichotomized
stain results (rather than using an H-score) to help compensate for possibly decreased stain
intensity, but there are likely some false-negative which weakens conclusions about any
possible associations. However, our findings are very consistent with the premise that ER is
likely the most predictive marker for response and survival with temsirolimus combined
with hormonal therapy. As expected, hormone receptor status does not appear to be
predictive of response to temsirolimus alone. Further work to find predictors of response to
mTOR inhibitors is clearly needed; KRAS mutations have been suggested to be associated
with resistance to mTOR inhibitor therapy, and this would be an interesting direction to
explore [32].
Interestingly, the overall survival for women with no prior chemotherapy on this study was
20.7 months, which well exceeds that seen in most prior front-line trials for endometrial
cancer, and at the very least suggests that the use of an mTOR inhibitor prior to
chemotherapy does not provide any survival disadvantage. The GOG reported median
overall survivals of 15.3 months with Taxol/doxorubicin/cisplatin [4] and 14 months with
the hormonal regimen on tamoxifen alternating with megestrol acetate [2] in chemotherapy-
naïve populations. However, it seems likely that optimal use of mTOR inhibitor therapy for
most women with endometrial carcinoma will be in combination with other agents. Results
of GOG 86P, which has an arm testing the combination of carboplatin, paclitaxel, and
temsirolimus followed by maintenance temsirolimus, should be available soon.
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• The combination of hormone therapy plus temsirolimus did not improve
response rates compared to temsirolimus alone.
• The combination of therapy with megestrol acetate/tamoxifen plus temsirolimus
resulted in a 33% rate of venous thrombosis
• Two of four patientss with clear cell carcinoma of the endometrium responded
to temsirolimus
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Figure 2a. PFS and OS by arm
Figure 2b. PFS and OS by prior therapy
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Figure 3a. OS by pAKT
Figure 3b OS by ER
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Immunohistochemistry for PTEN and pAKT
Immunostaining for PTEN and pAKT in the same tumor, demonstrating the expected
inverse correlation between loss of PTEN and activation of AKT.
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Table 1
Trials of Single-Agent mTOR Inhibitors in Endometrial Cancer
Author Agent Prior Chemotherapy Regimens RR
0za et al (17) Temsirolimus None 14%
0za et al (17) Temsirolimus 1–2 4%
Slomovitz et al (19) Everolimus 1–2 0
Ray-Coquard et al (33) Everolimus 1–2 6.8%
Colombo et al (34) Ridaforolimus IV 0–2 11%
Mackay et al (35) Ridaforolimus PO Adjuvant only 7.7
0za et al (29) Ridaforolimus 1–2 0
RR=response rate; IV=intravenous; PO= per os (orally)
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